{"preliminary_commentary":{"by_channel":{"x_thread":3},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":[["sasanlimab","stereotactic body radiation therapy"]],"indication":"cisplatin-ineligible muscle invasive bladder cancer","name":"RAD VACCINE MIBC","nct_id":"NCT05241340","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=rad-vaccine-mibc-nct05241340. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"RAD-VACCINE","arms":[{"description":"All patients will receive study interventions (sasanlimab and SBRT) and standard-of-care radical cystectomy.","label":"Open arm","type":"EXPERIMENTAL"}],"collaborators":["Pfizer"],"completion_date":{"date":"2027-04-01","type":"ESTIMATED"},"conditions":["Urothelial Carcinoma Bladder"],"enrollment":{"count":33,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Sasanlimab","otherNames":["PF-06801591","PD-1 Inhibitor"],"type":"DRUG"},{"name":"Stereotactic Body Radiation Therapy","otherNames":[],"type":"RADIATION"},{"name":"Radical Cystectomy + pelvic lymph node dissection + urinary diversion","otherNames":[],"type":"PROCEDURE"}],"last_update":"2025-10-24","lead_sponsor":"The Methodist Hospital Research Institute","official_title":"A Phase II Clinical Trial of Neoadjuvant Sasanlimab and Stereotactic Body Radiation Therapy as an in Situ Vaccine for Cisplatin-ineligible Muscle Invasive Bladder Cancer","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2025-08-01","type":"ACTUAL"},"primary_outcomes":[{"measure":"Composite outcome for Feasibility and Safety","timeFrame":"From date of registration to date of death due to any cause, assessed up to 4 weeks after radical cystectomy"},{"measure":"Clinical benefit rate defined as pathologic complete response (pT0)","timeFrame":"At time of radical cystectomy"}],"references":[{"citation":"Satkunasivam R, Lim K, Teh BS, Guzman J, Zhang J, Farach A, Chen SH, Wallis CJ, Efstathiou E, Esnaola NF, Sonpavde GP. A phase II clinical trial of neoadjuvant sasanlimab and stereotactic body radiation therapy as an in situ vaccine for cisplatin-ineligible MIBC: the RAD VACCINE MIBC trial. Future Oncol. 2022 Aug;18(25):2771-2781. doi: 10.2217/fon-2022-0380. Epub 2022 Jun 15.","pmid":"35703113","type":"DERIVED"}],"start_date":{"date":"2022-02-15","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Neoadjuvant Sasanlimab With Radiation as an in Situ Vaccine for Cisplatin-ineligible Muscle Invasive Bladder Cancer","url":"https://clinicaltrials.gov/study/NCT05241340"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.2","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/rad-vaccine-mibc-nct05241340"}